Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity

INTRODUCTION: Antiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and la...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, James H., Cottu, Paul H., Lehr, Martin, Dick, Evan, Shearer, Todd, Rencher, William, Bexon, Alice S., Campone, Mario, Varga, Andrea, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497701/
https://www.ncbi.nlm.nih.gov/pubmed/32594454
http://dx.doi.org/10.1007/s40264-020-00964-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497701/
https://www.ncbi.nlm.nih.gov/pubmed/32594454
http://dx.doi.org/10.1007/s40264-020-00964-x

Ejemplares similares